Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the highest safe dose and examine the side effects
and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML)
treated with chemotherapy that have not responded to previous therapy or have suffered a
relapse